The round attracted prominent leaders in AI and biotech, including new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.

本轮融资吸引了人工智能和生物技术领域的知名领袖，包括新投资者Amplo和Salesforce创始人兼首席执行官马克·贝尼奥夫（Marc Benioff），以及现有投资者Metaplanet、Humba Ventures、Atypical Ventures、Undeterred Capital和杰夫·迪恩（Jeff Dean）。

Parallel Bio is pioneering human-first drug discovery by combining organoids and AI to create true-to-life models of human biology. The company developed the first platform that replicates the human immune system across diverse populations, predicting drug success and identifying disease targets with accuracy and speed far beyond the limits of traditional animal models.

Parallel Bio 通过结合类器官和人工智能，开创了以人为本的药物发现方法，创造出逼真的人体生物学模型。该公司开发了首个能够复制不同人群人类免疫系统的平台，可以准确快速地预测药物成功率并识别疾病靶点，远远超越传统动物模型的局限性。

Pharmaceutical partners, including three Fortune 500 companies, are using its Clinical Trial in a Dish to test the safety and efficacy of immunotherapies. Based in Cambridge, Mass., Parallel Bio was founded in 2021 by two scientists behind the world's first scalable human immune organoid..

包括三家《财富》500强公司在内的制药合作伙伴正在使用其“盘中的临床试验”来测试免疫疗法的安全性和有效性。Parallel Bio 总部位于马萨诸塞州剑桥市，由两位科学家于2021年创立，他们曾参与开发了世界上第一个可扩展的人类免疫类器官。